Using the Montreal Cognitive Assessment Scale to screen for dementia in Chinese patients with Parkinson’s disease

Ling CHEN1#, Cuiyu YU2#, Xiaosu FU1, Weiguo LIU2*, Ping HUA2, Ning ZHANG2, Shenghan GUO3

Background: Dementia is one of the most distressing and burdensome health problems associated with Parkinson’s disease (PD). The Montreal Cognitive Assessment scale (MoCA) is widely used to screen for dementia in PD patients, but the appropriate diagnostic cutoff score when used with Chinese PD patients is not known.

Aim: Determine the appropriate diagnostic cutoff value of the Chinese version of the MoCA (MoCA-C) for Chinese PD patients and describe the characteristics of PD patients screened positive for dementia using the MoCA-C.

Methods: The presence of dementia in 616 PD patients and 85 community controls was determined using the Movement Disorder Society Task Force (MDS-TF) criteria (the gold standard diagnosis). We administered the MoCA-C to these individuals and used a receiver operating characteristic (ROC) curve to identify the cutoff score of the MoCA-C that most efficiently identified dementia in both PD patients and community controls. Demographic and clinical characteristics of PD patients who were screened positive or negative for dementia using the MoCA-C were compared.

Results: A MoCA-C score of 23 was the optimal cutoff score for dementia in both patients and controls. Using this cutoff score, the sensitivity and specificity of the MoCA-C in PD patients were 0.70 and 0.77, respectively; the positive and negative predictive values were 0.59 and 0.85, respectively; and the overall concordance of the MoCA-C screening result with the MDS-TF diagnosis (kappa value [95% confidence interval]) was 0.45 (0.39-0.52). The concordance of the MoCA-C screening result with the MDS-TF diagnosis in community controls was only 0.25 (0.05-0.45). Compared to PD patients who screened negative for dementia, those who screened positive for dementia were significantly more impaired in all cognitive domains, including visuospatial and executive functioning, naming, attention, language, abstraction, delayed recall and orientation (all \( p < 0.001 \)).

Among the PD patients, screening positive for dementia was independently associated with old age, low educational attainment, female gender and more severe motor impairment.

Conclusions: The commonly recommended cutoff screening score for dementia of 26 on the MoCA it too high for PD patients in China; a cutoff score of 23 is more appropriate. Potential risk factors for dementia in Chinese PD patients include older age, less education, and more severe motor symptoms of PD.

1. Introduction
Parkinson’s disease (PD) was once primarily described as a movement disorder, but there is now increasing recognition that the clinical features of PD also include non-motor symptoms, particularly cognitive impairment and dementia.\(^1\) The estimated prevalence of dementia in PD patients ranges from 24 to 31%.\(^2\) The cognitive profile of PD dementia (PD-D) includes severe and extensive deficits in executive functions, attention, memory, and visuospatial abilities.\(^1\) Compared to PD patients without dementia, those with dementia have a shorter life expectancy and a lower quality of life, so early recognition is key for the prevention and treatment of PD-D.\(^3\)

Diagnosis of dementia in PD using the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)\(^4\) is often difficult due to the old age and poor motor functioning of most PD
of other neurological conditions (including cerebral infarction, cerebral hemorrhage, brain tumor, and brain trauma), sensory impairments, depression (Hamilton Depression Scale\(^{[16]}\) score >20), atypical clinical symptoms of PD or poor drug treatment effect (suggesting a questionable diagnosis of PD), or having less than 10 years of education. The recommended MMSE cutoff score of 26 (used when making the gold standard MDS-TF diagnosis of dementia) is only appropriate for respondents under 80 years of age with at least 10 years of formal education, so PD patients who didn’t meet these criteria were excluded.

The control group were a convenience sample of community members living in three neighborhoods in Nanjing who met the following criteria: (a) 50 to 80 years of age; (b) at least 10 years of formal education; (c) did not have PD or other neurological or mental disorders, and (d) not using any psychotropic medications. Among the 91 potential community control subjects identified, six were excluded due to a history of mental disorder, neurological disease or drug abuse.

All participants were able to speak Mandarin and signed informed consent before their demographics information was obtained. The study was approved by the Ethics Committee of the Nanjing Medical University.

2.2 Assessments

Enrolled PD patients and community controls were classified into those with and without dementia using the MDS-TF criteria by a movement disorder specialist (author WL). As a part of making the MDS-TF diagnosis of dementia, all subjects were tested with the MMSE. Both MMSE and MoCA-C assess a range of cognitive skills on a scale of 0 to 30 points with higher scores indicating better performance. Believing that it would be best to make the assessments with the two scales at the same time, and considering the substantial overlap of several questions in the two scales, we decided to re-group individual items of the scales into four cognitive domains (visuospatial, language, memory, and orientation) based on previous research.\(^{[17]}\) The visuospatial items include design copy (both tests) and figure drawing to command (only MoCA-C). The language items include object naming (both tests), phrase/sentence repetition (both tests), verbal commands (only MMSE), and reading comprehension (only MMSE). The verbal memory items include recall of either five (MoCA-C) or three (MMSE) previously presented words. The MoCA-C also includes a fifth domain about executive function and attention that has items about phonemic fluency and visuospatial sequencing and alternation.

Chinese versions of the following instruments were also administrated to PD patients (but not to community controls) to assess PD motor symptoms, PD non-motor symptoms, depression, and anxiety: part III of the United Parkinson’s Disease Rating Scale (UPDRS).\(^{[18]}\)
part V of the UPDRS (the modified Hoehn and Yahr staging of Parkinson’s disease), Parkinson’s Disease Non-Motor Symptoms questionnaire (PD NMS), Parkinson’s Disease Sleep Scale (PDSS) (higher scores represent better sleep quality), Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), Zung Self-rating Depression Scale (SDS), and Zung Self-rating Anxiety Scale (SAS).

All scales were administered by two trained neurologists. A week after the initial assessment ten community controls were randomly selected to retest MMSE and MoCA-C; the test-retest reliability (interclass correlation coefficient [ICC]) was 0.63 and 0.71, respectively. Test-retest reliability (ICC) values for the full battery of scales among 40 patients who were retested 2 to 4 weeks after the initial evaluation were as follows: MMSE=0.72; MoCA-C=0.69; PD NMS=0.76; UPDRS=0.71; PDSS=0.55; HAMA=0.56; HAMD=0.66.

2.3 Statistical analysis

All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago IL). Chi-squared tests, Mann-Whitney rank tests (Z-tests), and t-tests were used to compare scores of MoCA-C and MMSE and other variables between groups. The significance level was set at 0.05.

To determine the screening cutoff score of MoCA-C, the MoCA-C scores of PD patients and of community controls with and without dementia (classified using the MDS-TF criteria) were compared. The predictive accuracy of different potential cutoff scores was assessed using the area under the receiver operating curve (AUC). For each possible cutoff score, the sensitivity and specificity were computed and differences in sensitivity and specificity were tested with McNemar’s tests. The score with the highest Youden Index score (which

Figure 1. Flow chart of the study
maximizes sensitivity and specificity, giving them equal weighting) was identified as the optimal cutoff score.

The newly determined cutoff score of MoCA-C was then used to divide PD patients into two groups, those who screen positive or negative for dementia using the MoCA-C. Standard Cohen’s kappa values were used to assess overall concordance of the MoCA-C screening results for dementia with the ‘gold standard’ diagnosis of dementia (i.e., based on MDS-TF criteria) and the 95% confidence intervals for kappa were assessed using the method proposed by Fleiss.23) The demographic and clinical characteristics of PD patients classified into these two groups (i.e., those screened positive or negative for dementia using the MoCA-C) were compared. Variables that were statistically significant in the univariate analysis were subsequently entered into a multivariate logistic regression analysis that used a stepwise method to identify variables independently associated with screening positive for dementia using the MoCA-C.

3. Results

3.1 Diagnosis of dementia

As shown in Figure 1, using the MDS-TF criteria as the gold standard, 196 (31.8%) of the 616 PD patients met the criteria for dementia and 42 (49.4%) of the 85 community controls met the criteria for dementia. The demographic characteristics of the PD patients with dementia (PD-D) were not significantly different from those of the PD patients without dementia (PD-ND): 57.7% (113/196) of PD-D patients versus 64.5% (271/420) of PD-ND patients were male ($x^2=2.69, p=0.101$); the mean (sd) age of PD-D patients was 68 (10) years versus 66 (11) years for PD-ND patients ($t=1.72, p=0.087$); and the mean age of onset of PD was 60 (10) years in the PD-D group versus 59 (11) years in the PD-ND group ($t=0.95, p=0.340$). Similarly, there were no significant differences in the characteristics of community controls who did and did not meet MDS-TF criteria of dementia: 57.1% (24/42) of community members with dementia were male versus 58.1% (25/43) of community members without dementia ($x^2=0.01, p=0.926$); and the mean age of those with dementia was 67 (11) years versus 63 (10) years in those without dementia ($t=1.74, p=0.086$).

3.2 Optimal cutoff score for dementia of the MoCA-C

The discriminatory validity of MoCA-C for detecting PD-D patients (defined using MDS-TF criteria) was examined using receiver operating characteristics (ROC) curves. As shown in Figure 2, the area under the curve (AUC) was 0.83 (95%CI=0.80-0.86) for PD patients. The biggest Youden Index was 0.48, and the optimal cutoff value was 22.5 (22/23). The sensitivity and specificity of this cutoff were 0.78 and 0.70, respectively.

The ROC analysis of the community control group is shown in Figure 3. Among the controls, the AUC was 0.87 (95%CI=0.79-0.95), the biggest Youden Index was 0.62, and the optimal cutoff value was 23.5 (23/24). The sensitivity and specificity of this cutoff were 0.81 and 0.81, respectively.

**Figure 2.** Receiver operating characteristics (ROC) curve of Chinese version of Montreal Cognitive Assessment (MoCA-C) for identifying dementia (defined by MDS-TF criteria) in Chinese patients with Parkinson’s disease

**Figure 3.** Receiver operating characteristics (ROC) curve of Chinese version of Montreal Cognitive Assessment (MoCA-C) for identifying dementia (defined by MDS-TF criteria) in Chinese community control subjects
Since the cutoff value was 22/23 among PD patients and 23/24 among controls, we took 23 as the threshold to identify dementia in both the patient group and the community control group. Using a score of 23 or lower on the MoCA-C to identify PD patients at risk for dementia and comparing these results to the gold standard diagnosis using MDS-TF criteria, the sensitivity and specificity of the MoCA-C were 0.70 and 0.77, respectively; the positive and negative predictive values were 0.59 and 0.85, respectively; and the overall concordance of the MOCA-C screening result with the MDS-TF diagnosis (kappa [95% confidence interval]) was 0.45 (0.38-0.52). In the community control group the sensitivity and specificity of MoCA-C for identifying those with dementia were 0.76 and 0.49, respectively; the positive and negative predictive values were 0.59 and 0.68, respectively; and the overall concordance (kappa) was 0.25 (0.05-0.45). In the PD patients, the concordance of the MoCA-C screening result for dementia with the MMSE screening result for dementia (i.e., scores <26 screen positive and scores ≥26 screen negative) was high (Kappa=0.80, 95% CI=0.75-0.91); the corresponding concordance of the dementia screening result of the MoCA-C and MMSE in community controls was fair (Kappa=0.67, 95% CI=0.52-0.82).

As shown in Table 1, for both the PD patient group and the community control group, individuals who screened positive for dementia using the MoCA-C total score of 23 had significantly poorer functioning than those who screened negative for dementia on all seven MoCA-C subscales (all p<0.001): visuospatial and executive functioning, naming, attention, language, abstraction, delayed recall, and orientation.

### 3.3 Comparison of PD patients who do and do not screen positive for dementia using the MoCA-C

The demographic and clinical results for the 235 PD patients who screened positive for dementia using the MoCA-C versus those of the 381 patients who screened negative for dementia are shown in Table 2. All variables assessed were significantly different between the two groups. Compared to those who screened negative for dementia using the MoCA-C, those who screened positive were more likely to be female, to be older, to have a lower level of education, and to have a later age of onset of PD; they also had more severe depressive and anxiety symptoms (both as assessed by the clinician and as self-reported), more severe non-motor and motor PD symptoms, a higher Hoehn and Yahr stage of PD, and more severe sleep disturbance (lower scores on the PDSS represent worse sleep quality).

The logistic regression results, which identify the demographic and clinical variables of PD patients independently associated with being screened positive for dementia (i.e., a score of less than 23 on the MoCA-C) are shown in Table 3. Similar to the univariate analysis, greater age, female gender and...
lower educational attainment were associated with being screened positive for dementia. Among the measures of the severity of PD, only more severe motor symptoms (i.e., higher scores on Part III of the UPDRS) was independently associated with screening positive for dementia. Somewhat surprisingly, none of the five psychological measures that were significant in the univariate analysis remained in the final multivariate model; this probably occurred because all of the psychological scales were strongly correlated with the severity of PD motor symptoms (correlation of the five scale scores with the score on Part III of UPDRS ranged from 0.25 to 0.37).

4. Discussion

4.1 Main findings

In this study, the proportion of PD patients with dementia was 38.2%, which is in accordance with previous findings.

\[2,26\] The optimal diagnostic cutoff scores for the MoCA-C determined in our study were 22/23 for PD-D patients and 23/24 for controls. Both were lower than the previously published normative

### Table 2. Demographic characteristics and clinical symptoms of Parkinson’s disease (PD) patients who do and do not screen positive for dementia on the Chinese version of the Montreal Cognitive Assessment (MoCA-C) scale

| Characteristic                              | Screen positive for dementia (n=235) | Screen negative for dementia (n=381) | statistic | p-value |
|---------------------------------------------|--------------------------------------|--------------------------------------|-----------|---------|
| Female (n [%])                              | 123 (53.0%)                          | 118 (34.3%)                          | \( \chi^2 = 19.94 \) | <0.001  |
| Age (mean [sd])                             | 69.3 (10.0)                          | 64.8 (10.6)                          | \( t = 5.04 \)     | <0.001  |
| Age of onset (mean [sd])                    | 60.8 (11.4)                          | 58.4 (10.9)                          | \( t = 2.54 \)     | 0.012   |
| Years of education (median [IQR])           | 9 (6-12)                             | 12 (9-15)                            | \( Z = 10.60 \)    | <0.001  |
| Depression (HAMD score) (median [IQR])      | 13 (7-21)                            | 10 (6-16)                            | \( Z = 3.67 \)     | <0.001  |
| Depression (SDS score) (median [IQR])       | 31 (26-37)                           | 29 (25-35)                           | \( Z = 2.90 \)     | 0.004   |
| Anxiety (HAMA score) (median [IQR])         | 11 (7-17)                            | 9 (4-14)                             | \( Z = 3.83 \)     | <0.001  |
| Anxiety (SAS score) (median [IQR])          | 30 (26-34)                           | 28 (25-34)                           | \( Z = 2.40 \)     | 0.017   |
| Sleep (PDSS score) (median [IQR])           | 116 (98-131)                         | 121 (108-135)                        | \( Z = 3.80 \)     | <0.001  |
| PD Non-motor symptoms (median [IQR])        | 12 (9-16)                            | 10 (6-14)                            | \( Z = 4.58 \)     | <0.001  |
| PD motor symptoms (score of Part III of UPDRS) (median[IQR]) | 34 (22-43) | 26 (24-28) | \( Z = 7.57 \)     | <0.001  |
| Hoehn and Yahr staging of PD (Part V of UPDRS) (median[IQR]) | 2.5 (2-3) | 2.0 (1.5-2.5) | \( Z = 5.15 \)     | <0.001  |

HAMD, Hamilton Depression Rating Scale
HAMA, Hamilton Anxiety Rating Scale
SDS, Zung Self-rating Depression Scale
PDSS, Parkinson’s Disease Sleep Scale
UPDRS, United Parkinson’s Disease Rating Scale

### Table 3. Demographic and clinical characteristics of 616 patients with Parkinson’s disease (PD) that are independently associated with screening positive for dementia on the Chinese version of the Montreal Cognitive Assessment (MoCA-C) scale

| Characteristic                              | p-value | odds ratio (95%CI) |
|---------------------------------------------|---------|--------------------|
| Age                                         | <0.001  | 1.06 (1.03-1.08)   |
| Male                                        | 0.045   | 0.60 (0.36-0.99)   |
| Years of education                          | <0.001  | 0.80 (0.75-0.85)   |
| Score on motor symptoms section in UPDRS    | <0.001  | 1.06 (1.04-1.08)   |

UPDRS, United Parkinson’s Disease Rating Scale
* Considering all variables that were significant in the univariate analysis (see Table 2), the multivariate logistic regression analysis first forced age, gender, and years of education into the model and then used a forward stepwise method to identify other significant variables. The Nagakerke R-squared for the final model was 0.406.
data for the MoCA. In fact, many researchers have recommended that the optimal cutoff value of MoCA for diagnosing dementia should be lower than 26. In a recent study, Wang and colleagues examined the sensitivity, specificity, and threshold scores of the MoCA-C in identifying dementia with Lewy bodies (DLB); the cutoff score they found was 22/23, which had a sensitivity of 91.7% and a specificity of 80.6% (AUC=0.932). When using a score of 26 as the cutoff, Nazem and colleagues found that PD patients who screened positive for dementia performed worse on only five out of seven MoCA subtests; the subscale scores for attention and abstraction were not significantly different between PD patients who screened positive and negative for dementia. Using a lower cutoff score of 23, we found that PD patients who screened positive for dementia differed significantly in all seven subtests of MoCA-C than those who screened negative for dementia, a difference that was also observed among controls. Therefore, using a MoCA-C score of 26 as the threshold to screen for dementia might falsely include PD patients (and, possibly, other types of individuals) whose global cognition is not sufficiently impaired to justify classification as dementia.

PD-D has been called a ‘dysexecutive dementia’, a condition that leads to a broader range of cognitive deficits than in Alzheimer’s dementia. Previous studies reported a higher prevalence of PD-D in patients with the postural instability and gait disorder (PIGD) motor subtype of PD. Mild cognitive impairment, older age and severe motor symptoms were also found to be risk factors for PD-D. Another study conducted by Levy and colleagues suggested that the combined effects of increasing age and more extrapyramidal signs is the primary factor that contributes to the elevated risk of dementia in patients with PD. Our study, which compared PD patients screened positive or negative for dementia using the MoCA-C cutoff score of 23, found that current age, lower educational attainment and the overall severity of motor impairment were independently associated with the development of dementia in PD patients. As measured by UPDRS III, PD patients who screened positive for dementia had much more difficulty in specific motor tasks than PD patients who screened negative for dementia. We also found that despite the lack of a significant difference in the prevalence of dementia (based on the MDS-TF criteria) between female patients with PD and male patients with PD, female patients with PD were more likely than male patients with PD to screen positive for dementia using the MoCA-C; further prospective studies using the MoCA-C are needed to clarify the reasons for this difference. Overall, our results both confirm the validity of the MoCA-C as a screening tool for dementia in PD patients and suggest that progressive motor disability has a synergistic effect with increasing age that elevates the risk of dementia among patients with PD.

4.2 Limitations

Several issues need to be considered when assessing these results. It is unclear how representative PD patients recruited from the Parkinson’s Disease Clinic of the Nanjing Brain Hospital are of all patients with PD; we expect that this sample is representative of urban patients in China who are receiving treatment for PD, but the characteristics of rural PD patients and of PD patients not receiving regular treatment may be quite different.

The relatively small number of community control subjects (n=85) and the very high prevalence of dementia in these subjects (49.4%) indicates that they were not representative of older community members as a whole. Most of these individuals were elderly residents who were available at home during the day, so many had physical disabilities and cognitive difficulties. The MoCA-C cutoff score identified for dementia in community members may be different if a more representative group of older urban community residents were chosen.

In order to simplify the administration of the survey, we integrated the items for MMSE and MoCA-C. This may have influenced respondents’ results so it is not certain that the MMSE scores and MoCA-C scores were the same as would occur if the two scales were administered independently.

We determined the optimal cutoff score for the MoCA-C using the Youden Index, which gives equal weight to sensitivity and specificity and, thus, assumes that false positive results are of equal importance as false negative results. If, however, the relative importance of false positive and false negative results when screening for a condition are different – which may be the case in dementia because of the stigma associated with the label and the current lack of effective treatments – there would be a need to adjust the cutoff score accordingly.

4.3 Implications

To our knowledge, this is the first report to determine the appropriate cutoff score of the Montreal Cognitive Assessment scale for identifying dementia in Chinese patients with Parkinson’s disease. We recommend a substantially lower cutoff score than has previously been recommended in other countries (23 v. 26) so the results have substantial clinical implications for the screening of Chinese PD patients, and, potentially, for the general population screening for dementia in China. Similar to other studies we found that PD patients who screen positive for dementia using the MoCA-C cutoff score were older, had a lower educational level, and had more severe PD motor symptoms; this suggests that further research is needed to clarify the interaction between motor impairment and cognitive impairment among patients with PD.
Conflict of interest
The authors declare no conflict of interest.

Acknowledgements
The authors would like to thank all the participating patients and community members.

Funding
The study was supported by the National Natural Science Foundation (81173039), the Jiangsu Province Medical Science and Technology Foundation Chinese Traditional Medicine Project (LB09088), the Nanjing Department of Health Medical Science and Technology Key Project Development Foundation (200905016), the American Academy of Neurology Research Fellowship, and the Parkinson’s Disease Foundation.

References
1. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis 2012; 46(3): 590-596.
2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20(10): 1255-1263.
3. Nussbaum M, Treves TA, Inzelberg R, Rabey JM, Korczyn AD. Survival in Parkinson’s disease: the effect of dementia. Parkinsonism Relat Disord 1998; 4(4): 179-181.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association, 1994.
5. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Dueñas M, Carod Artal FJ, Rojo Abuin JM, et al. Dementia associated with Parkinson’s disease: recommendations from the movement disorder society task force. Mov Disord 2007; 22(16): 2314-2324.
6. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22(16): 2314-2324.
7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51(6): 745-752.
8. Zhang MY. Handbook of Scales Used in Psychiatry. Changsha: Hunan Science and Technology Press; 1998. p. 166-168. (in Chinese)
9. Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 2008; 23(2): 297-299.
10. Dong Y, Sharma VK, Chan BP, Venkatasubramanian N, Tech HL, Seet RC, et al. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010; 299(1): 15-18.
11. Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijimn M, Sakuma N, et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 2010; 10(3): 225-232.
12. Lee JY, Dong WL, Cho SJ, Na DL, Hong JJ, Maeng JC. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008; 21(2): 104-110.
13. Wong A, Xiong YY, Kwan PW, Chan AY, Lam WW, Wang K, et al. The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. Dement Geriatr Cogn Disord 2009; 28(1): 81-87.
14. Rossetti HC, Lactritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011; 77(21): 1272-1275.
15. Hu JB, Zhou WH, Hu SH, Huang ML, Wei N, Qi HL, et al. Cross-cultural difference and validation of the Chinese version of the Montreal Cognitive Assessment in older adults residing in Eastern China: preliminary findings. Arch Gerontol Geriatr 2013; 56(1): 38-43.
16. Wang XD (ed). Rating Scales for Mental Health, revised edition. Beijing: Chinese Journal of Mental Health Press; 1999. p. 196-199. (in Chinese)
17. Mickes L, Jacobson M, Peavy G, Wiexed JT, Lessig S, Goldstein JL, et al. A comparison of two brief screening measures of cognitive impairment in Huntington’s disease. Mov Disord 2010; 25(13): 2229-2233.
18. United Parkinson’s Disease Rating Scale (UPDRS version 3.0) Chinese Journal of Geriatrics 1999; 18(1): 61-62. (in Chinese)
19. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov Disord 2006; 21(7): 916-923
20. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73(6): 629-635.
21. Zhang MY. Handbook of Scales Used in Psychiatry. Changsha: Hunan Science and Technology Press; 1998. p. 35-39. (in Chinese)
22. Wang ZY, Chi YF. Zung self-rating Depression Scale (SDS). Shanghai Archives of Psychiatry 1984; 2: 71-72. (in Chinese)
23. Wang ZY, Chi YF. Zung self-rating Anxiety Scale (SAS). Shanghai Archives of Psychiatry 1984; 2: 73-74. (in Chinese)
24. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47(4): 458-472.
25. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions, 3rd Edition. Hoboken, New Jersey: John Wiley & Sons; 2003.
26. Dong Y, Lee WY, Basri NA, Collinson SL, Merchant RA, Venkatasubramanian N, et al. The Montreal Cognitive Assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia. Int Psychogeriatr 2012; 24(11): 1749-1755.
27. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009; 73(21): 1738-1745.

28. Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC. Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer’s disease, and normal participants in Taiwan. Int Psychogeriatr 2013; Aug 7: 1-10. (Epub ahead of print)

29. Nazem S, Siderowf AD, Duda JE, Have TT, Colcher A, Horn SS, et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc 2009; 57(2): 304-308.

30. Emre M, Aarsland D, Brown R, Burn DJ, Duyskaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22(12): 1689-1707.

31. Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 2006; 77(5): 585-589.

32. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55(4): 539-544.

33. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 2010; 20(3): 633-639.

34. Levy G, Jacobs DM, Tang MX, Côté LI, Louis ED, Alfaro B, et al. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 2002; 17(6): 1221-1226.

(received: 2013-07-24, accepted: 2013-09-16)

Ling Chen obtained her bachelor’s degree in psychological health from the 4th School of Clinical Medicine at Nanjing Medical University in 2008. She received her master’s degree in applied psychology in 2011 from the same institution. She is currently working in the Jiangsu Province Official Hospital as a resident doctor and in the Department of Neuropsychology.

Cuiyu Yu received her bachelor’s degree in clinical medicine from Bingzhou Medical College in 2011. She is currently a master’s degree candidate in neurology in the 4th School of Clinical Medicine at Nanjing Medical University. She is also working as an intern in the Department of Internal Neurology at the Nanjing Brain Hospital.
蒙特利尔认知评估量表在中国帕金森氏病患者中筛查痴呆的应用

背景：痴呆是帕金森氏病(PD)相关的最痛苦和最繁重的健康问题之一。蒙特利尔认知评估量表(MOCA)被广泛用于帕金森氏症患者的痴呆筛查，但是不知道怎样的诊断划界分适用于中国的帕金森病患者。

目的：确定中国版蒙特利尔认知评估量表(MoCA-C)在中国帕金森氏症患者中的诊断划界分和了解经MoCA-C筛查痴呆阳性的帕金森氏症患者的特征。

方法：采用运动障碍学会工作组标准(金标准诊断)确定616例PD患者和85名社区对照中是否存在痴呆。我们对这些人进行了MoCA-C测试，并运用受试者工作特征(ROC)曲线来确定能够最有效地识别帕金森氏症患者和社区对照中痴呆的MoCA-C划界分。比较经MoCA-C筛查为痴呆阳性与阴性的PD患者的人口学和临床特征。

结果：MoCA-C23分是诊断帕金森氏患者及对照组痴呆的最佳划分。使用该划分，PD患者的MoCA-C敏感性和特异性分别为0.70和0.77，阳性预测值分别为0.59和0.85，一致性(kappa [95%可信区间])为0.45(0.39-0.52)。社区对照的kappa值(一致性)仅为0.25(0.05-0.45)。与筛查为痴呆阴性的PD患者相比，筛查为痴呆阳性的PD患者认知功能都有显著受损，包括视觉空间和执行功能，命名，注意力，语言，抽象，延迟回忆和定向(均P<0.001)。在帕金森氏症患者中，筛查为痴呆阳性与年老，文化程度低，女性以及严重运动障碍独立相关。

结论：通常建议的痴呆划分26分对于中国帕金森病患者来说过高；23分划分更加合适。中国的帕金森氏症患者发生痴呆的可能危险因素包括年龄，文化程度低，以及PD严重的运动障碍症状。